admin

BioTalk Host Rich Bendis sits down with Anne Lindblad, Ph.D., President, and CEO of Emmes, to discuss her view of the region, her history with the company, and their mission, vision, and values.

Anne Lindblad, Ph.D., joined Emmes in 1982 as a Biostatistician and is currently the President and CEO. She has supported clinical research throughout her career, serving as Principal Investigator of projects spanning diverse disease areas, including neurology, ophthalmology, oncology, dialysis, transplantation, speech and hearing, and dentistry. Dr. Lindblad has been an NIH reviewer on multiple project applications for NINDS, NEI, NICHD, NIDCR, NIDDK, and NCCAM and has served as a member or chair of several Data and Safety Monitoring Committees for NEI, NIAAA, NIDDK, and NINDS. She was a member of an Advisory Committee charged with drafting policy to shape the appropriate planning and conduct of intramural studies at NIH. She was elected to the Board of Directors for the Society for Clinical Trials (2003-2006) and served as Program Chair (2002), as an Officer (2006-2014), and as President (2012-2013). Dr. Lindblad was selected to serve on NIH’s National Advisory Dental and Craniofacial Research Council from 2004 through 2008. She has taught courses in best practices in clinical trial design and conduct for ophthalmologists, neurologists, and immunologists. She has published and presented over 100 manuscripts in peer-reviewed journals and conferences. Dr. Lindblad joined the Board of BioHealth Innovation in 2018.  Emmes has grown from 15 employees in 1982 to over 650 globally. In 2019 Emmes announced a significant investment by Behrman Capital which will allow Emmes to gain access to new tools, talent, service offerings, and expanded footprint faster than what Emmes might otherwise have accomplished.

Listen now on iTunes, Google Play, and TuneIn. 

Read More

April 8 + 9, 2019

One MedImmune Way, Gaithersburg, MD 20878

This invitation-only event is free for executive level biotech leaders and is presented by BioHealth Innovation, VirginiaBio, Maryland Tech Council, University System of Maryland, Children’s National Health Network, HemoShear, GSK, BeneVir, Quality Biological, Johns Hopkins University and AstraZeneca. Maryland, Virginia, and Washington, DC set the bar high for biotech innovation. So please join us for our Annual BioHealth Capital Region Forum that will highlight the accomplishments of today and chart our successes of tomorrow.

REGISTER TODAY!

Register at bhcrf2019.eventbrite.com

For more information about our speakers and event schedule, please visit www.bhcrforum.com.

Read More

Columbia-based Osiris is coming off a tumultuous three-year period in which four CEOs left the company and several former executives faced criminal charges for fraud.

Read More

It all begins at birth. That’s the starting point for Kurt Newman as he shares his poignant journey as a pediatric surgeon. Newman offers a new perspective for approaching the most chronic and debilitating health conditions. Against a backdrop of personal challenges and patients who overcame impossible odds, we learn to appreciate the importance of treating every child with early customized care, and an eye for the future.

Read More

MCEDC discovers how Greg’s clinical-stage company in Montgomery County, MD is using bacteria phage to combat the worldwide crisis in multi-drug resistant bacterial infections.

Read More

Just as the drug pricing debate on Capitol Hill is heating up, an important new study, “The Bayh-Dole Act’s Vital Importance to the U.S. Life-Sciences Innovation System,” published by the Information Technology & Innovation Foundation (ITIF), underscores the law’s contribution to the United States’ lead in the life sciences. The report warns that attempts to misuse the march-in rights provision of the law to control drug prices would have serious consequences to our competitiveness and our health.

Read More

• PR and Marketing – What’s the difference?
• How do you establish your brand?
• Are their tips for marketing on a tight budget?
• What should an effective marketing plan include?
• How can a strong digital strategy build credibility?
• How can I get press coverage for my product/service/technology?
• What type of budget is realistic for marketing/public relations activities?

Learn the answers to these questions and more through the April 4th PathFinder Innovation Program. (There is no charge to attend in person or by videoconference, however, pre-registration by NOON, 4/2 is required).

8:15 a.m. Networking and Coffee8:30 a.m.  – Issues Overview and Discussion (in person/by videoconference)

• Pam Clark, Principal, Creative Director – Clark Concepts
• Warren Ellis, VP of Marketing, Montgomery County Economic Development Corp.
• Rachel Wojnilower, Digital Marketing Manager – Clark Concepts
• Jennifer Owers, WebDesigner/Project Manager – Clark Concepts

9:45 a.m. – 1:1 Office Hours (in person/by videoconference)*

This program is cosponsored by BioHealth Innovation, Launch Workplaces, and TEDCO. It is open to anyone in the BioHealth Capital Region.  

To register/for more information, email:  BHI@BioHealthInnovation.   (Please include in your RSVP:  Your company name, your title and contact information, the type of product(s) services you are promoting, and your interest in a 1:1 meeting following the overview session.)

*Attendance at Overview in person/by videoconference is required to participate in 1:1 sessions.

Read More

In 1942, Austrian economist Joseph Schumpeter wrote, “ …industrial mutation—if I may use that biological term—that incessantly revolutionizes the economic structure from within, incessantly destroying the old one, incessantly creating a new one. This process of Creative Destruction is the essential fact about capitalism.”

Read More

The Universities at Shady Grove (USG) will hold a Undergraduate Expo Saturday, Apr. 6 from 9 a.m. to noon. USG is part of the University System of Maryland and offers approximately 80 undergraduate and graduate degree programs from nine different state universities on the Rockville campus.

Read More

Alexandria Real Estate Equities, Inc. (“Alexandria” or the “Company”) (NYSE: ARE) today announced that it has priced a public offering of $200,000,000 aggregate principal amount of 4.000% senior notes due 2024, $350,000,000 aggregate principal amount of 3.800% senior notes due 2026 and $300,000,000 aggregate principal amount of 4.850% senior notes due 2049. Goldman Sachs & Co. LLC, Citigroup Global Markets Inc., J.P. Morgan Securities LLC and SMBC Nikko Securities America, Inc. are acting as joint book-running managers in connection with the public offering and Barclays Capital Inc., BB&T Capital Markets, a division of BB&T Securities, LLC, BBVA Securities Inc., BNP Paribas Securities Corp., Capital One Securities, Inc., Evercore Group L.L.C., Fifth Third Securities, Inc., Mizuho Securities USA LLC, PNC Capital Markets LLC, RBC Capital Markets, LLC, Regions Securities LLC, Samuel A. Ramirez & Company, Inc., Scotia Capital (USA) Inc., SunTrust Robinson Humphrey, Inc., TD Securities (USA) LLC, U.S. Bancorp Investments, Inc. and Wells Fargo Securities, LLC are acting as co‑managers in connection with the public offering.

Read More

Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics, today announced that it has applied the CE mark to PGDx elio™ plasma resolve. It is the first kitted plasma-based NGS oncology test to have that certification, enabling greater access to genomic testing for cancer patients in Europe.

Read More

Sonavex is first targeting the reconstructive surgery market with its new medical technology, which just earned its final FDA clearance.

Read More

A pair of Baltimore healthcare leaders are partnering to reach digital health startups.

Hospital network LifeBridge Health and health insurance provider CareFirst BlueCross Blue Shield will be hosting an innovation challenge that includes a chance to pitch and win funding for companies.

Read More

It didn’t take long for the Trump administration to tap Ned Sharpless, now director of the National Cancer Institute, to take the reins at FDA for now—or for biopharma to hail the news. In fact, one team of analysts said the industry would “breathe a collective sigh of relief.”

Read More

Eargo, a direct-to-consumer health technology company that is destigmatizing hearing loss through innovation, announced it raised $52 million in Series D funding from existing investors New Enterprise Associates (NEA), the Charles and Helen Schwab Foundation, Nan Fung Life Sciences, and Maveron. And new investor Future Fund also participated in this round.

Read More

The joint health-care venture between Amazon AMZN , J.P. Morgan JPM and Berkshire Hathaway BRK.A finally has a name: “Haven.”

Read More

For American patients aching for relief from the sky-high price of drugs, the news has been decidedly mixed recently.

Read More

The part of your brain responsible for ASMR catalogs music, and appears to be a stronghold against Alzheimer’s and dementia.

Read More

The already much-heralded University of Texas MD Anderson Cancer Center has just scored global bragging rights. James Allison, Ph.D., a scientist at MD Anderson Cancer Center, has been awarded the 2018 Nobel Prize in Physiology or Medicine, it was announced on October 1.

Read More

YOU THOUGHT SHARK TANK WAS TOUGH?

APPLY NOW!

Submit your application for a chance to be named the Startup with the Most Commercial Potential at the BioHealth Capital Region Forum, win $10,000 and more!

APPLICATION DEADLINE: March 15, 2019

FINALISTS ANNOUNCED: March 21, 2019

PRESENT AT THE BIOHEALTH CAPITAL REGION FORUM APRIL 9, 2019PRESENT AT THE BIOHEALTH CAPITAL REGION FORUM APRIL 9, 2019

Finalists will have a chance to win the grand prize by presenting in front of a panel of prominent industry funding experts and executives.

Distinguished Judges:

Moderator – Rich Bendis, President and CEO, BioHealth Innovation

2019 Judges

• John Rubin, Executive Director, JP Morgan Private Bank
• Charles J. Andres, Intellectual Property Associate, Wilson Sonsini Goodrich & Rosati (WSGR)
• Raghav Bhargava, Associate, New Enterprise Associates (NEA)
• Ethel Rubin, Entrepreneur in Residence, NIH
• Shaun Grady, Vice-President Business Development Operations, AstraZeneca
• Norm Marcus, MD, Venture Partner, Sanderling Ventures 

PRIZES

Grand Prize provided by WSGR $10,000

Visibility in front of hundreds of attendees and prominent industry and venture capital judges

CRITERIA

Product, Technical Feasibility, Marketing/Strategy, Leadership Team, Financial/Projection

PAST WINNERS: Sonavex (2016) LifeSprout (2017) Galen Robotics (2018)

Read More

April 8 + 9, 2019

One MedImmune Way, Gaithersburg, MD 20878

This invitation-only event is free for executive level biotech leaders and is presented by BioHealth Innovation, VirginiaBio, Maryland Tech Council, University System of Maryland, Children’s National Health Network, HemoShear, GSK, BeneVir, Quality Biological, Johns Hopkins University and AstraZeneca. Maryland, Virginia, and Washington, DC set the bar high for biotech innovation. So please join us for our Annual BioHealth Capital Region Forum that will highlight the accomplishments of today and chart our successes of tomorrow.

Register at bhcrf2019.eventbrite.com

For more information about our speakers and event schedule, please visit www.bhcrforum.com.

Read More

Emmes today announced that Behrman Capital, a leading private equity firm, has made a significant investment in the company. The capital will allow Emmes, one of the Washington area’s top 100 largest private companies, to expand and strengthen its service offerings and international presence.

Read More

Sonavex, Inc., a privately held medical device company focused on empowered patient care, announced today that on March 8, 2019 it received 510(k) clearance from the U.S. Food and Drug Administration for its EchoSure device to deliver definitive blood flow data on demand.

Read More

• PR and Marketing – What’s the difference?
• How do you establish your brand?
• Are their tips for marketing on a tight budget?
• What should an effective marketing plan include?
• How can a strong digital strategy build credibility?
• How can I get press coverage for my product/service/technology?
• What type of budget is realistic for marketing/public relations activities?

Learn the answers to these questions and more through the April 4th PathFinder Innovation Program. (There is no charge to attend in person or by videoconference, however, pre-registration by NOON, 4/2 is required).

8:15 a.m. Networking and Coffee8:30 a.m. – Issues Overview and Discussion (in person/by videoconference)

• Pam Clark, Principal, Creative Director – Clark Concepts
• Warren Ellis, VP of Marketing, Montgomery County Economic Development Corp.
• Rachel Wojnilower, Digital Marketing Manager – Clark Concepts
• Jennifer Owers, WebDesigner/Project Manager – Clark Concepts

9:45 a.m. – 1:1 Office Hours (in person/by videoconference)*

This program is cosponsored by BioHealth Innovation, Launch Workplaces, and TEDCO. It is open to anyone in the BioHealth Capital Region.

To register/for more information, email: BHI@BioHealthInnovation. (Please include in your RSVP: Your company name, your title and contact information, the type of product(s) services you are promoting, and your interest in a 1:1 meeting following the overview session.)

*Attendance at Overview in person/by videoconference is required to participate in 1:1 sessions.

Read More

Are you a start-up in Maryland, DC or Virginia seeking feedback on your biohealth business idea, pitch deck, or commercialization plan?  Sign up by noon 3/19 to schedule your feedback session with BHI Entrepreneurs-in-Residence (who have industry experience in therapeutics, Dx, medtech and more) next Wednesday, March 20th.  (The next session is scheduled for 3/20 and 5/22.)  Pre-registration is required; sign up here(“EIR resource” at BHI).  For questions/more information, contact BHI.

Read More

The Maryland Technology Development Corporation (TEDCO), Maryland’s economic engine for technology companies, announced today the findings of an independent economic impact study detailing the economic development contributions of TEDCO’s five core programs to the state of Maryland.

Read More

Four Johns Hopkins professors received grants through a fund created to help faculty put their research on a path to commercialization.

The professors received grants between $25,000 and $100,000 from the Bisciotti Foundation Translational Fund.

Read More

UMB has long been one of the state’s most powerful economic drivers, stimulating $3 billion in economic activity in 2018, up from $2.8 billion in 2016. A significant factor in that growth is the UM BioPark, which occupies 14 acres in West Baltimore providing laboratory and office space to 41 biotechnology companies and over 1,000 employees.

Read More

The National Capital Consortium for Pediatric Device Innovation is accepting applications for its Make Your Medical Device Pitch for Kids competition.

Read More

Three investment firms topped the list of local tech investors in the DMV region according to CB Insights‘ report, The United States of Venture Capital.

Read More

One woman is making her mark at the highest level of U.S. local politics.

She was born in China and successfully carved her path all the way to the state capitol.

CGTN’s Frances Kuo has her story.

Read More

On Wednesday, MACo Legislative Committee members Craig Rice (Montgomery), Jan Gardner (Frederick), and Laura Price (Talbot) joined Executive Director Michael Sanderson in support of SB 1030 The Blueprint for Maryland’s Future.

Read More

Cell therapy is emerging, cell by cell, into the repertoire of medical therapies. However, it still has not broken into mainstream use. For instance, there are only two FDA-approved chimeric antigen receptor (CAR) T-cell treatments in the United States: Kymirah, Novartis’s treatment for acute lymphoblastic leukemia, and Yescarta, Kite Pharma’s treatment for non-Hodgkin’s lymphoma.

Read More

Visibility, speaking out, courage and organization. Forty years ago, these were the things that brought the Orphan Drug Act to life. On Sunday, February 24, across the U.S. and India, over 7,000 supporters gathered in the same passion: speaking out and bringing visibility to the more than 7,000 disorders collectively known as rare diseases, organized under the banner of Racefor7USA and its parent organizations, the Organization for Rare Disease India (ORDI) and Organization for Rare Diseases India in the U.S. (ORDIUSA).

Read More

Cutting Edge Lab Space Available

The NIH is the cornerstone to the world scientific community and is the largest life sciences engine in the US.

Bethesda Bio gives life science companies the ability to be on the doorstep of this invaluable wealth of resources, community, talent, technology, intellectual property, clinical studies. The existing Bethesda central business district provides a vibrant live, work and play environment to recruit and retain the best scientific minds. Over the past two decades, Bethesda has been the center of Montgomery County and the hub of innovation.

Read More

An HIV-positive man in Britain has become the second known adult worldwide to be cleared of the AIDS virus after he received a bone marrow transplant from an HIV resistant donor, his doctors said.

Read More

YOU THOUGHT SHARK TANK WAS TOUGH?

APPLY NOW!

Submit your application for a chance to be named the Startup with the Most Commercial Potential at the BioHealth Capital Region Forum, win $10,000 and more!

APPLICATION DEADLINE: March 15, 2019

FINALISTS ANNOUNCED: March 21, 2019

PRESENT AT THE BIOHEALTH CAPITAL REGION FORUM APRIL 9, 2019PRESENT AT THE BIOHEALTH CAPITAL REGION FORUM APRIL 9, 2019

Finalists will have a chance to win the grand prize by presenting in front of a panel of prominent industry funding experts and executives.

Distinguished Judges:

Moderator – Rich Bendis, President and CEO, BioHealth Innovation

2019 Judges

• John Rubin, Executive Director, JP Morgan Private Bank
• Charles J. Andres, Intellectual Property Associate, Wilson Sonsini Goodrich & Rosati (WSGR)
• Raghav Bhargava, Associate, New Enterprise Associates (NEA)
• Ethel Rubin, Entrepreneur in Residence, NIH
• Shaun Grady, Vice-President Business Development Operations, AstraZeneca
• Norm Marcus, MD, Venture Partner, Sanderling Ventures 

PRIZES

Grand Prize provided by WSGR $10,000

Visibility in front of hundreds of attendees and prominent industry and venture capital judges

CRITERIA

Product, Technical Feasibility, Marketing/Strategy, Leadership Team, Financial/Projection

Read More

April 8 + 9, 2019

One MedImmune Way, Gaithersburg, MD 20878

This invitation-only event is free for executive level biotech leaders and is presented by BioHealth Innovation, VirginiaBio, Maryland Tech Council, University System of Maryland, Children’s National Health Network, HemoShear, GSK, BeneVir, Quality Biological, Johns Hopkins University and AstraZeneca. Maryland, Virginia, and Washington, DC set the bar high for biotech innovation. So please join us for our Annual BioHealth Capital Region Forum that will highlight the accomplishments of today and chart our successes of tomorrow.

Register at bhcrf2019.eventbrite.com

For more information about our speakers and event schedule, please visit www.bhcrforum.com.

Read More

More than 120 people registered for last week’s SBIR Workshop at IBBR organized by BioHealth Innovation in partnership with Launch Workplaces and support from TEDCO and NIH FCU.  

The event featured program overviews, “how to” sessions regarding specific aspects of proposal development and 1:1 partnering meetings with the program managers.  

Speakers included:  Todd Haim,  Ph.D., Chief, Office of Small Business Research NIA;  Mike Pieck, Ph.D., Small Business Coordinator, NHLBI; Maureen (Cusick) Thomas, Outreach Coordinator, NIA;Victor Prikhodko, Business Advisor, NIDA; Amir Rahbar, PhD, MBA, Program Director, NCI;  Vladimir M. Popov, PhD, Business Dev. Manager, NCI-FNL;Amir Rahbar, PhD, MBA, Program Director, NCI; Henry Ahn, Program Director SBIR/STTR, NSF; and Colleen Gibney, SBIR Deputy Project Mgr, USAMRMC.  

44% of the attendees had applied for SBIR funding before with half of these innovators receiving a Phase 1.  Only 16% had received a Phase II award.  The majority of attendees were from Montgomery and Frederick Counties and the City of Baltimore.  However, registrants also traveled from Virginia, DC, Illinois and Pennsylvania.

Read More

Are you a start-up in Maryland, DC or Virginia seeking feedback on your biohealth business idea, pitch deck, or commercialization plan?  Sign up by noon 3/19 to schedule your feedback session with BHI Entrepreneurs-in-Residence, who have industry experience in therapeutics, Dx, medtech and more March 20th.  (Future session scheduled for 5/22.)  Pre-registration is required; sign up here (“EIR resource” at BHI).  For questions/more information, contact BHI.

Read More

MaxCyte, the global cell-based medicines and life sciences company, announced today that it has expanded its relationship with Kite, a Gilead Company, by entering into a multi-drug clinical and commercial agreement. Under the terms of the agreement, Kite will use MaxCyte’s Flow Electroporation® Technology to enable non-viral cell engineering for development of multiple CAR-T drug candidates for up to 10 targets.

Read More

The company has already raised about $40 million to date.

Read More

Emergent BioSolutions announced today that the company has signed a deal with the U.S. Department of State to establish a supply chain for certain medical countermeasures that address chemical warfare agents.

Read More

The National Capital Consortium for Pediatric Device Innovation (NCC-PDI) is now accepting applications for its “Make Your Medical Device Pitch for Kids!” competition. The competition is focused on pediatric devices developed for use in the orthopedic and spine sector, an area of critical need which lacks innovation. Winning companies receive awards up to $50,000 and are invited to participate in the newly created NCC-PDI “Pediatric Device Innovator Accelerator Program” led by MedTech Innovator.

Read More

Gilead’s Kite Pharma has expanded its CAR-T agreement with MaxCyte. The revised deal gives Kite the chance to apply MaxCyte’s transfection technology to up to 10 targets.

Read More

Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical stage biopharmaceutical company developing innovative therapies to improve patient outcomes in cancers that are difficult to treat, today announced the appointment of Lara S. Sullivan, M.D. to its board of directors.

Read More

Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics, announced today that it has added two new members to its Board of Directors, Dr. Kavita Patel and Garry Allen Nicholson. Dr. Patel and Mr. Nicholson bring significant healthcare expertise that is aligned with and can further empower PGDx’s corporate growth strategy of driving global access to precision medicine in oncology.

Read More

For every AstraZeneca, there are hundreds of small biotech startups and scores of life science innovators that are critical to growing the BioHealth Capital Region. For every new biotech flush with investment cash, scores of smart, entrepreneur-scientists with great ideas and technology struggle to find regional funding partners.

Read More

Dr. Darryl Sampey has been through the grind as CEO of Frederick’s BioFactura, a thriving biotech company that’s a key part of the BioHealth Capital Region’s second largest biotech hub. On a rainy, cold February night at FITCI, Sampey shared BioFactura’s compelling story during a “fireside chat” hosted by StartUp Grind’s Frederick chapter.

Read More

When: Wednesday, March 13, 2019 from 5:00 PM to 7:00 PM

Where: Bar Louie 150 Gibbs St Rockville, MD 20850

Join BioBuzz and Founding Sponsor JHU MoCo for our next exciting event of 2019 at Bar Louie in Rockville on March 13th. 

The Johns Hopkins University Krieger School of Arts and Sciences created the Center for Biotechnology Education to engage diverse audiences in the world of biotechnology and to prepare the leaders of today, tomorrow and the next generation for the challenges of the 21st century.

Read More

In late 2017, Baltimore-based healthcare startup Protenus was reverberating from a year of growth.

Read More

I was dubious when Crystal Icenhour approached me to write about her medical testing company.

Read More

The National Cancer Institute’s investment in small business research grants has supported strong economic growth, including $9 billion in sales of new technologies.

Read More

Justin Klein, as a former investor with NEA, helped lead PGDx’s $21.4 million Series A in 2015 and its $75 million Series B last year.

Read More

The biotech sector has been a strong performer in 2019 after becoming quite oversold during the plunge in the high-beta parts of the market in the fourth quarter of 2018. Helping the sector recover and get off to a raucous start to the New Year were large buyouts of Celgene Corp(CELG) and Loxo Oncology Inc(LOXO) to start 2019, both with significan…

Read More

New Enterprise Associates, the 41-year-old venture firm with offices in Menlo Park; San Francisco; Boston; New York; Chevy Chase, Md.; and Washington, D.C., is raising its biggest fund ever, shows a new SEC filing that shows target of $3.6 billion.

Read More

Office REIT Alexandria Real Estate Equities reports it has launched a new product geared to providing post-seed-stage life science companies with turnkey, fully furnished office/laboratory suites.

Read More

Francis deSouza Photographer: Jeff Spicer/PA Wire via AP For years, the cost to decode a full human genome has been falling much like computer processing costs — from hundreds of thousands of dollars per person to about $1,000 today. With a $100 genome getting closer, the CEO of the top maker of DNA sequencers thinks the world may not be ready.

Read More

The biomedical research community has made major progress in achieving a balance of men and women in human studies, however compelling questions about the underlying mechanisms that increase women’s risk or resilience for certain heart, lung, blood, and sleep (HLBS) diseases continue to challenge the scientific and medical community.

In support of its Strategic Vision, the National Heart, Lung, and Blood Institute (NHLBI) is advancing a scientific research agenda for women’s health. As part of that agenda, the Institute has issued a Request for Information “Understanding the Health of Women and the Role of Sex/Gender in Mechanisms of Heart, Lung, Blood, and Sleep Diseases and Disorders.” The RFI offers the research community, health care professionals, patient advocates, and others an opportunity to provide input on topics ranging from scientific gap areas in mechanisms of HLBS diseases, to training and resource needs, among other topics.

The NHLBI greatly values your perspective as it works with the wider scientific community to uncover the mechanisms of disease that will set a stronger foundation for clinical research focused on more effective prevention and treatment strategies for HLBS diseases and disorders in women. Please submit your responses via email to WHWGRFI@nhlbi.nih.gov by March 15, 2019. Don’t forget to include the Notice number (NOT-HL-18-660) in the subject line.

Read More

The share of funding going to women-founded startups went down despite a massive influx of dollars to the region.

Read More

Albert Bourla told a US Senate hearing that other nations are “free-riding on American innovation”.

Read More

Biopharma companies have long been looking for a way to go beyond the molecule/pill.The nascent but growing digital therapeutics industry set to grow to $10 billion by 2023 may be guiding that way forward, according to a panel discussion on the second day of the DTx (Digital Therapeutics) West conference in San Mateo, California.

Read More

Funding for the Bethesda-based National Institutes of Health is up by 14 percent during the two years that President Donald Trump has been in the White House — but it’s despite and not because of the president, according to Maryland Sen. Chris Van Hollen.

Read More

Johns Hopkins researchers have developed a unique, noninvasive blood test that detects proteins and gene mutations from eight common cancers. The test, called CancerSEEK, screens for cancers that account for more than 60 percent of U.S. cancer deaths.

Read More

In November 2015, infectious disease epidemiologist Steffanie Strathdee and her husband, evolutionary psychologist Tom Patterson, were spending the week of Thanksgiving exploring pyramids and pharaoh’s tombs in Egypt when Patterson came down with what seemed like a nasty bout of food poisoning aboard their cruise ship. But as his condition rapidly deteriorated and he had to be emergency medevac’d, first to Germany and then to the medical center at UC San Diego, where both scientists were on staff, blood and imaging tests revealed why Patterson’s body was failing. A soccer-ball-sized cyst in his abdomen was infected—teeming with one of the most dangerous, antibiotic-resistant bacteria in the world.

Read More